Form 4: Elicio Therapeutics Director Converts Convertible Note into Common Stock

Yekaterina Chudnovsky, a director and 10% owner of Elicio Therapeutics, converted a convertible note held by GKCC, LLC into common stock on March 5, 2025.

Summary

• On March 5, 2025, Yekaterina Chudnovsky, a director and 10% owner of Elicio Therapeutics, converted a convertible note into common stock.
• The conversion was executed at a price of $5.81 per share.
• The convertible note, including any accrued but unpaid interest, was converted into 3,442,341 shares of common stock.
• Following the transaction, Ms. Chudnovsky indirectly beneficially owns 5,416,212 shares of common stock through GKCC, LLC.
• The convertible note had a stated maturity date of February 15, 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard transaction (conversion of debt to equity) by a director, which doesn't inherently indicate positive or negative sentiment.

Positives

• The conversion of the note into equity could be seen as a positive sign, indicating confidence in the company's future prospects.

Risks

• The conversion increases the number of outstanding shares, which could potentially dilute existing shareholders' ownership.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders.

Stakeholder Impact

• Shareholders may experience dilution due to the increase in the number of outstanding shares.

Key Dates